Category: News

The new version of InSyBio Suite enables the fast and accurate discovery of transcriptomics predictive biomarkers.

• The newly introduced pipeline in InSyBio ncRNAseq tool offers efficient, user friendly and secure pre-processing of RNA-sequencing data without having to manually define parameters or select the best algorithm to be used in each step.
• The interpretation of the revealed biosignatures is now reaching a supreme level with our patent pending functional annotation and enrichment tools as well as our network analytics techniques.
• This new version will enable users generating transcriptomics data to join InSyBio Suite userss community and speed up the accomplishment of their research tasks towards high quality scientific publications and top research outcomes.

InSyBio Suite version 2.5 has been officially launched as of Monday May 9th, 2019. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated that “Our transcriptome contains information combining our genetic predisposition and more advanced epigenetic mechanisms. With the new version of InSyBio Suite we enable the discovery of predictive biomarkers and models from transcriptomics data in an unbiased, error-free optimal manner”.

InSyBio Suite now offers the following unique features:

• In InSyBio ncRNAseq tool: An optimized semi-automatically adjusted pipeline for the RNA-sequencing data (fastq or bam files) linked with the rest of the biomarker discovery pipeline offered by InSyBio Suite.
• In InSyBio Interact tool: Access to a human interactome knowledge base using our patent-pending technology 1 which includes functional annotation of more than 95% of the human proteome. New functional enrichment functionalities were also incorporated.
• In InSyBio BioNets tool: Incorporation of prior knowledge networks into the process of reconstructing biological networks with correlation or mutual information-based mechanisms.

The CEO of InSyBio, Labros Digonis, stated that “According to recent reports the global transcriptomics market is expected to exceed $3B in 2019 with the RNA-sequencing services part of it being one of the fastest growing. At InSyBio, we had been servicing this market previously with tools for the analysis of non-coding RNAs but were continuously getting requests from the users of our platform and our collaborators for a pipeline for the preprocessing and analysis of RNA-sequencing data reducing the number of parameters that the user need define. Our group of programmers and researchers did their best [work] during the last months and we are now able to offer a user-friendly interface for our RNA-sequencing pre-processing pipeline which can provide results fast, is linked to the rest of our platform’s functionality and requires minimum bioinformatics expertise by the users. Our company’s vision is to act as a catalyst to accelerate discovery of novel biomarkers from multi-omics data and speed up the disruption of the pharma industry in the new era of precision medicine.”

1. K Theofilatos, C Dimitrakopoulos, S Mavroudi, A Korfiati, C Alexakos, Protein functional and sub-cellular annotation in a proteome, US Patent App. 15/361,461

InSyBio is offering a one-month free license to use InSyBio Suite including the new version of ncRNAseq tool. Request your free trial now by completing a simple form at: https://www.insybio.com/request.html

About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .

For more News visit our InSyBio Blog.

InSyBio’s R&D team applying the company’s proprietary predictive biomarker technology to a collection of data from open omics repositories came up with a novel biosignature of 13 transcripts and a predictive model for glioblastoma diagnosis and treatment. The biosignature not only increases significantly the diagnostic accuracy for glioblastoma but it is able to differentiate it from other types of brain tumors. Additional validation experiments are planned by InSyBio team, as this biosignature, combined with the trained machine learning models can become a strong tool in the hands of physicians not only for diagnostic-screening purposes but also for personalizing glioblastoma treatment by classifying patients into meaningful genomic phenotypes.

This work entitled as “Combining Network Theory and Machine Learning to Identify a Diagnostic and Prognostic Biosignature for Glioblastoma” was accepted for a poster presentation (poster #54) at the 11th Annual RECOMB/ISCB Conference on Regulatory & Systems Genomics, 10-12 December 2018, New York. It will be presented on the Poster Session 5:30 pm – 7:00 pm on Monday 10th of December 2018.

Mackenzie Hastings, the neuroscientist of InSyBio, business development associate and the company’s representative in the conference stated: “Glioblastoma is the most aggressive and lethal form of brain cancer but with InSyBio’s novel approach of biological network comparison, we were able to take an unparalleled leap in the pursuit of better diagnosis and treatment through our discovery of a novel, 13-transcript biomarker signature capable of diagnosing both tumor subtype and genetic profile with higher predictive accuracy than any other state-of-the-art method”. Mackenzie will be present in all three days of the conference and everyone interested in arranging an one-to-one meeting with her in the context of the conference should contact her before the conference via email at m.hastings@insybio.com .

InSyBio’s CEO, Labros Digonis, stated that: “InSyBio has been enrolled for the fight against cancer and specifically against aggressive, currently untreated forms of Cancer such as Glioblastoma. RECOMB/ISCB is considered among the top international conferences for computational and systems biology research and we consider it as a perfect match for us to present our research. Though our participation in this conference we are seeking for collaborators which can contribute to validating and interpreting the glioblastoma biosignature we have uncovered as well as molecular biologists who can benefit from the utilization of our biomarker discovery technology”.

About the conference: The RECOMB/ISCB Conference on Regulatory and Systems Genomics with DREAM Challenges (https://www.iscb.org/recomb-regsysgen2018) is one of the premier annual meetings in the fields of regulatory genomics, systems biology, and network visualization. This multidisciplinary conference brings together both computational and experimental researchers from across the world to discuss recent discoveries about genomic and molecular regulatory networks as well as innovative, integrative methods for developing a systems-level understanding of biological activity.

About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research goals (such as robust biomarker discovery and accurate predictive models). Since 2013, InSyBio has worked with hundreds of academics, companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an average increase of 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

InSyBio participates in the NBG Business Seeds and the International Accelerator Programs.

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .

For more News visit our InSyBio Blog.

The new version of InSyBio Suite has a significant increase in speed and refinement of the predictive biomarkers process.

• The pioneer InSyBio Biomarkers tool is a unique tool offering single and multi-omics biomarker discovery with a combination of statistical, machine learning and biological network methods.
• It allows its users to use InSyBio’s patent pending pipeline for biomarker discovery with increased predictive accuracy and decreased requirements for sample size and validation experiments.
• with this new version the company keeps innovating whilst focused on its mission to transform and improve the world of precision medicine, ultimately guaranteeing safer and more effective treatments.
• this new version will improve the experience of more than 400 active users of InSyBio Suite and help them succeed in their research tasks.

InSyBio Suite version 2.4 has been officially launched on Monday 26th of November 2018. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated that “At InSyBio we are crazy enough to think that we can revolutionize the biomarker discovery process – and maybe we have”.

InSyBio Biomarkers tool offers the following key features:

• Data preprocessing using a combination of normalization, filtering, scaling and missing values imputation techniques.
• Semi-automatic statistical analysis: automatically select the best statistical test for your dataset.
• Bioinformatics visualization of your omics data with heatmaps, volcano plots, boxplots and excel-like tabular files.
• Identification of multiple biomarker solutions and training machine learning predictors with them.
• Using trained machine learning models and identified multiple biomarkers to predict the phenotype on new data.

Other important updates include:

• Functional characterization of >95% of the human proteome using our patent-pending in silico pipeline.
• New advanced technique for miRNA target prediction using as input a series of a set of genes and a set of miRNAs and exploring all the potential miRNA:mRNA target sites among them with a computational technique which provides >98% accuracy.
• Extended changes in the interface of the tool to improve user experience.

The CEO of InSyBio, Labros Digonis, stated that “Big data—and, more importantly, its effective analysis—enable an unprecedented understanding of the world around us, and make it possible to improve Pharmaceutical and Food/Nutrition Industries to work more effectively and efficiently. Knowing the great added value the Suite brings on, we believe the Insybio Suite will be established as the analysis platform of choice, ‘the SAP’ for Pharma and Nutrition Industries’ R&D”.

About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research goals (such as robust biomarker discovery and accurate predictive models). Since 2013, InSyBio has worked with hundreds of academics, companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an average increase of 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

InSyBio participates in the NBG Business Seeds and the International Accelerator Programs.

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .

For more News visit our InSyBio Blog.

InSyBio is the latest startup company to join the International Accelerator program in Austin, Texas USA (https://www.internationalaccelerator.com/) with an ultimate goal to get access to the USA biotechnology market.

Labros Digonis, the CEO of InSyBio, who holds a MBA and Master’s Degree in Naval Architecture & Marine Engineering and has over 30 years of experience in top-management positions in multibillion groups and as management consultant in several Industries, stated about InSyBio’s collaboration with the International Accelerator that “We don’t only share common interests but the same vision and passion which trancends a common partnership; it’s a strategic alliance to create something great to not only serve America but the World!”

InSyBio joined IA’s program to expand their operations in North America, as well as gain access to institutional investors to expedite their growth. IA’s program is unique as they invest exclusively in foreign-born entrepreneurs. The 12-month customized program is designed for portfolio companies to gain access to the U.S. market and secure venture capital funding for growth opportunities. In addition, each portfolio companies receives a hand selected mentor, a deep dive strategic and operational roadmap to success, 12-months of free working space, $50,000 in seed funding, and a host of other value-add services.

About InSyBio: InSyBio is a privately held, global bioinformatics company (www.insybio.com) focusing, through advanced biological big-data computational tools, on biomarkers discovery for Cancer, Neurodegenerative diseases and Nutrition. Biomarker extraction from biological big data (genomics, transcriptomics, proteomics, etc.) is essential for drug discovery & research acceleration, personalized medicine and Nutrition.

InSyBio’s patented breakthrough technology offers unique inside path to an integrated end-to-end accurate biomarker discovery process, simultaneous integration of data from different sources and types and has demonstrated ability to locate significantly more common proteins in large scale proteomics datasets. At InSyBio, the team is passionate about supporting customers to minimize their efforts, as they design and develop new drugs, therapeutic and diagnostic methods.

About International Accelerator: The International Accelerator is the only U.S. accelerator focused solely on investing in companies with non-U.S. citizen founders. IA provides access to seed funding, quality mentors, and services foreign-born entrepreneurs need to scale up their businesses in the United States. The International Accelerator is more than an accelerator program. It is a trusted co-founder for stateside ventures and dedicated to helping non-U.S. citizen entrepreneurs set up their U.S. company, give it an “American look and feel,” and lay a sturdy foundation to build a global business. The experienced team leverages years of international business, design, and entrepreneurial expertise, as well as access to industry experts, active investors and potential customers. At IA, the goal is to bring startups in and send them out with impressive products and the capability to stand on their own feet. Being entrepreneurs themselves, they clearly know the hardships and worries of the startup process. Apart from money, IA is always available to give the help customized for the founder, so they can focus on their product and developing their vision for the company.

For more News visit our InSyBio Blog.

We are proud to announce that InSyBio is the winner of the Investor Prize in the category of Big Data for Health in Sanofi’s “Tech for health” Lab in VivaTech 2017 event (https://vivatechnology.com/) which was held at Paris, 15-17 June, 2017.

InSyBio was one of the 34 innovative companies sponsored by Sanofi to join the Viva Technology 2017 event. In this event, we presented our biomarker discovery platform (InSyBio Suite) as a solution able to be a catalyst in accelerating Pharma clinical trials being achieved through the identification of key predictive biomarkers for i) drug toxicity and disease progression and ii) drug efficacy.

By winning the Investor’s prize InSyBio was given with the opportunity to discuss with top executives of Sanofi for a potential investment in our company, while is now in close contact with various Sanofi’s R&D departments to explore the applicability of InSyBio’s solution in various clinical trials and data analytics research projects of Sanofi around the world.

InSyBio’s experience in the VivaTech Event was exciting and gave our scientists the opportunity to get in touch with the pharma, nutrition and cosmetics ecosystems and industrial clusters in France. Additionally, several collaborations have been initiated with French IT and biotechnology companies for co-development and co-selling activities while InSyBio have also found strong interest from investors for the participation to its current Series A financing round.

InSyBio’s participation in the VivaTech 2017 event was supported by the French Embassy in Greece/ French Institute of Greece and the “Mazinnov” project, French Embassy’s initiative for the creation of bridges between Greek and French innovation ecosystems.

About InSyBio: InSyBio is a bioinformatics pioneer company in personalized healthcare which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data, aiming at the discovery of predictive integrated biomarkers (biomarkers of various categories) with applications in pharma, nutrition and cosmetics industries.

Find more details at www.insybio.com .

For more News visit our InSyBio Blog.